CA2229140A1 - Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage - Google Patents

Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage Download PDF

Info

Publication number
CA2229140A1
CA2229140A1 CA002229140A CA2229140A CA2229140A1 CA 2229140 A1 CA2229140 A1 CA 2229140A1 CA 002229140 A CA002229140 A CA 002229140A CA 2229140 A CA2229140 A CA 2229140A CA 2229140 A1 CA2229140 A1 CA 2229140A1
Authority
CA
Canada
Prior art keywords
selectin antibody
selectin
antibody
ser
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002229140A
Other languages
English (en)
French (fr)
Inventor
Anton Haselbeck
Gunther Schumacher
Man Sung Co
Ulrich Martin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Scil Biomedicals GmbH
PDL Biopharma Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2229140A1 publication Critical patent/CA2229140A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2851Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72
    • C07K16/2854Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the lectin superfamily, e.g. CD23, CD72 against selectins, e.g. CD62
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • External Artificial Organs (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
CA002229140A 1995-08-17 1996-08-14 Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage Abandoned CA2229140A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP95112895.8 1995-08-17
EP95112895 1995-08-17
EP95114696 1995-09-19
EP95114696.8 1995-09-19
US57895395A 1995-12-27 1995-12-27
US08/578,953 1995-12-27

Publications (1)

Publication Number Publication Date
CA2229140A1 true CA2229140A1 (en) 1997-02-27

Family

ID=27236574

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002229140A Abandoned CA2229140A1 (en) 1995-08-17 1996-08-14 Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage

Country Status (11)

Country Link
EP (1) EP0868197B1 (enExample)
JP (1) JP3604699B2 (enExample)
AT (1) ATE265861T1 (enExample)
AU (1) AU6773596A (enExample)
CA (1) CA2229140A1 (enExample)
CZ (1) CZ45498A3 (enExample)
DE (1) DE69632407T2 (enExample)
HU (1) HUP9901673A3 (enExample)
PL (1) PL187090B1 (enExample)
WO (1) WO1997006822A1 (enExample)
ZA (1) ZA966954B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5994511A (en) 1997-07-02 1999-11-30 Genentech, Inc. Anti-IgE antibodies and methods of improving polypeptides
US6172213B1 (en) 1997-07-02 2001-01-09 Genentech, Inc. Anti-IgE antibodies and method of improving polypeptides
GB9919713D0 (en) 1999-08-19 1999-10-20 Queen Mary & Westfield College New medical use of high density lipoprotein
CN1646160A (zh) 2002-03-13 2005-07-27 拜奥根Idec马萨诸塞公司 抗αvβ6抗体
CN102875681A (zh) * 2005-07-08 2013-01-16 拜奥根Idec马萨诸塞公司 抗-αvβ6抗体及其用途
SG173364A1 (en) 2006-07-10 2011-08-29 Biogen Idec Inc Compositions and methods for inhibiting growth of smad4-deficient cancers
WO2014144466A1 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2014143739A2 (en) 2013-03-15 2014-09-18 Biogen Idec Ma Inc. Anti-alpha v beta 6 antibodies and uses thereof
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
CN121197633A (zh) 2019-12-13 2025-12-26 比特比德科有限责任公司 用于将治疗剂递送至胃肠道的可摄取装置

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2305192A (en) * 1991-06-25 1993-01-25 Dana-Farber Cancer Institute Monoclonal antibody to lymphocyte-associated cell surface protein
WO1993002698A1 (en) * 1991-07-29 1993-02-18 Dana-Farber Cancer Institute, Inc. Monoclonal antibodies to leukocyte adhesion molecule-1
CA2149025A1 (en) * 1992-12-01 1994-06-09 Man Sung Co Humanized antibodies reactive with l-selectin
AU2185195A (en) * 1993-11-30 1995-06-19 Protein Design Labs, Inc. Reperfusion therapy using antibodies to L-selectin

Also Published As

Publication number Publication date
DE69632407T2 (de) 2005-06-02
JP3604699B2 (ja) 2004-12-22
ZA966954B (en) 1998-02-16
WO1997006822A1 (en) 1997-02-27
AU6773596A (en) 1997-03-12
ATE265861T1 (de) 2004-05-15
CZ45498A3 (cs) 1999-01-13
PL187090B1 (pl) 2004-05-31
EP0868197A4 (enExample) 1998-11-18
EP0868197A1 (en) 1998-10-07
PL325012A1 (en) 1998-07-06
JPH10510553A (ja) 1998-10-13
DE69632407D1 (de) 2004-06-09
HUP9901673A2 (hu) 1999-08-30
HUP9901673A3 (en) 2001-06-28
EP0868197B1 (en) 2004-05-06

Similar Documents

Publication Publication Date Title
Kukielka et al. Interleukin-8 gene induction in the myocardium after ischemia and reperfusion in vivo.
US20230364179A1 (en) Inhibition of trem receptor signaling with peptide variants
US5928893A (en) Monoclonal antibody specific for human 4-1BB and cell line producing same
US7317090B2 (en) Antibodies to Interleukin-4 receptors and uses thereof
Kroshus et al. Complement inhibition with an anti-C5 monoclonal antibody prevents acute cardiac tissue injury in an ex vivo model of pig-to-human xenotransplantation.
EP0751962B1 (en) Methods for inhibiting cd14 mediated cell activation
WO2002036164A1 (en) Blooe vegf level-lowering agent containing il-6 antagonist as the active ingredient
WO2005061000A1 (ja) 血管炎治療剤
CA2625773A1 (en) Inhibition of interleukin-6 (il-6) receptor promotes pancreatic islet transplantation
HUT71790A (en) Humanized antibodies reactive with l-selectin
AU2008265983A1 (en) RAGE fusion proteins
EP0868197B1 (en) Anti-l-selectin antibodies for prevention of multiple organ failure and acute organ damage
CA2344049C (en) Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway
CN113637070A (zh) 抗spike蛋白的抗体或抗原结合片段及其应用
AU746888B2 (en) Anti-selectin antibodies for prevention of multiple organ failure and acute organ damage
Kushimoto et al. Pulmonary vascular injury induced by hemorrhagic shock is mediated by P-selectin in rats
US20020098183A1 (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation
US5843441A (en) Use of endothelial-leukocyte adhesion molecule-1 specific antibodies in the treatment of asthma
TW520289B (en) Anti-selectin antibodies for prevention of multiple organ failure after polytrauma and for prevention of acute organ damage after extracorporeal blood circulation
US20100172909A1 (en) Cerebral edema suppressant
US5310551A (en) Method for inhibiting pulmonary oxygen toxicity
CooPER et al. Use of yttrium-90-labeled anti-Tac antibody in primate xenograft transplantation
EP4706639A1 (en) Complement binding fusion protein
MX2008004901A (es) Agentes para suprimir el daño a islotes trasplantados despues del trasplante del islote.
HK1001462B (en) Ligand (act-4-l) to a receptor on the surface of activated cd4+ t-cells

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued